Breaking News Instant updates and real-time market news.

EPZM

Epizyme

18:47
04/09/18
04/09
18:47
04/09/18
18:47

Epizyme publishes Phase 1 Tazemetostat study in The Lancet Oncology

Epizym announced its first-in-human data on the effects of EZH2 inhibition in patients with advanced solid tumors and B-cell non-Hodgkin lymphoma was published in the peer-reviewed The Lancet Oncology. The objectives of the Phase 1 dose-escalation portion of the study were to evaluate the safety and tolerability of orally dosed tazemetostat, a first-in-class selective inhibitor of EZH2. The study established the recommended dose for the Phase 2 expansion study and demonstrated favorable safety findings and anti-tumor activity. The open-label Phase 1 study was designed to evaluate the maximally tolerated dose and supported defining the recommended Phase 2 dose of tazemetostat. Tazemetostat was dosed twice daily as a single agent in patients with relapsed or refractory B-cell NHL or with advanced solid tumors including molecularly defined INI1- or SMARCA4-negative tumors. Additional study objectives were to evaluate the adverse events, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of the agent. The results of the safety, PK and PD analyses helped determine the RP2D of 800 mg twice daily. The most common treatment-related adverse events, regardless of attribution, were grade 1 or 2 asthenia, anorexia, anemia, muscle spasms, nausea and vomiting. One single dose-limiting toxicity of grade 4 thrombocytopenia was identified at the highest dose of 1600 mg, but no other grade 3 or 4 toxicities were observed at a frequency greater than 5%.

  • 25

    Apr

EPZM Epizyme

03/14/18
RHCO
03/14/18
NO CHANGE
Target $27
RHCO
Buy
Epizyme price target raised to $27 from $21 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Epizyme to $27, saying the company's Q4 earnings call reiterated expectations of on-track data flow in epithelioid sarcoma registrations / NDA filing later this year, the combo data for DLBCL, and the follicular lymphoma data and registration path in the second half of 2018. Lawson keeps his Buy rating and attributes his price target revision to the treatment's higher probability of success.
02/01/18
02/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Roth Capital. 2. Take-Two (TTWO) initiated with an Overweight at Morgan Stanley. 3. AMERI Holdings (AMRH) initiated with an Outperform at Northland. 4. Simply Good Foods (SMPl) initiated with a Buy at SunTrust. 5. Zynerba (ZYNE) assumed with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/01/18
ROTH
02/01/18
INITIATION
Target $24
ROTH
Buy
Epizyme initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Epizyme with a Buy rating and $24 price target as he believes its lead agent tazemetostat, an inhibitor of the histone methyltrasferase EZH2, has laid out a sufficiently wide clinical footprint, and is sufficiently close to an NDA in several indications, that even his conservative approach of ranking its clinical programs shows that the company still remains undervalued.
01/24/18
JEFF
01/24/18
INITIATION
Target $25
JEFF
Buy
Epizyme assumed with a Buy at Jefferies
Jefferies analyst Michael Yee assumed coverage of Epizyme with a Buy rating and raised his price target for the shares to $25 from $23. The company represents an "attractive smid-cap cancer play" with lead drug tazemetostat having activity across a broad range of tumors, Yee tells investors in a research note.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$284.67

2.87 (1.02%)

, SPX

S&P 500

$0.00

(0.00%)

13:19
08/16/18
08/16
13:19
08/16/18
13:19
Periodicals
U.S. and China to hold lower-level trade talks later in August, Reuters says »

A Chinese delegation …

SPY

SPDR S&P 500 ETF Trust

$284.67

2.87 (1.02%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:19
08/16/18
08/16
13:19
08/16/18
13:19
Hot Stocks
Breaking Hot Stocks news story  »

Rosehill Resources Inc…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
08/16/18
08/16
13:17
08/16/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
08/16/18
08/16
13:16
08/16/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRP

TransCanada

$43.81

0.04 (0.09%)

13:13
08/16/18
08/16
13:13
08/16/18
13:13
Periodicals
Federal judge orders review of Keystone XL oil pipeline, Reuters reports »

In the latest setback for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$23.39

0.92 (4.09%)

, MYL

Mylan

$37.94

0.12 (0.32%)

13:05
08/16/18
08/16
13:05
08/16/18
13:05
Hot Stocks
Teva granted FDA approval of first generic version of EpiPen »

The U.S. Food and Drug…

TEVA

Teva

$23.39

0.92 (4.09%)

MYL

Mylan

$37.94

0.12 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

GOOG

Alphabet

$1,223.00

9.35 (0.77%)

, GOOGL

Alphabet Class A

$1,239.00

6.7 (0.54%)

13:05
08/16/18
08/16
13:05
08/16/18
13:05
Periodicals
Google workers upset about company making censored engine for China, NYT says »

Hundreds of Google…

GOOG

Alphabet

$1,223.00

9.35 (0.77%)

GOOGL

Alphabet Class A

$1,239.00

6.7 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

13:04
08/16/18
08/16
13:04
08/16/18
13:04
Conference/Events
CFTC to hold a podcast on Agriculture Block Trade Analysis »

Dave Amato, of the U.S.…

HAFC

Hanmi Financial

$25.70

0.4 (1.58%)

13:04
08/16/18
08/16
13:04
08/16/18
13:04
Hot Stocks
Hanmi Financial announces receipt of all regulatory approvals for SWNB merger »

Hanmi Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

CLF

Cleveland-Cliffs

$9.89

0.05 (0.51%)

13:00
08/16/18
08/16
13:00
08/16/18
13:00
Options
Repeat call spreads in Cleveland Cliffs »

Repeat call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

NWBI

Northwest Bancshares

$18.31

0.12 (0.66%)

13:00
08/16/18
08/16
13:00
08/16/18
13:00
Hot Stocks
Northwest Bancshares chairman William Wagner sells over 64K shares »

Northwest Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$23.47

1 (4.45%)

, MYL

Mylan

$37.84

0.02 (0.05%)

12:57
08/16/18
08/16
12:57
08/16/18
12:57
Hot Stocks
Teva rises, Mylan dips after FDA reported to approve first generic EpiPen »

Shares of Mylan (MYL)…

TEVA

Teva

$23.47

1 (4.45%)

MYL

Mylan

$37.84

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

MYL

Mylan

$37.85

0.03 (0.08%)

, TEVA

Teva

$23.45

0.975 (4.34%)

12:53
08/16/18
08/16
12:53
08/16/18
12:53
Periodicals
Breaking Periodicals news story on Mylan, Teva »

FDA approves Teva generic…

MYL

Mylan

$37.85

0.03 (0.08%)

TEVA

Teva

$23.45

0.975 (4.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

  • 10

    Sep

  • 16

    Sep

  • 13

    Nov

DE

Deere

$137.51

1.81 (1.33%)

12:51
08/16/18
08/16
12:51
08/16/18
12:51
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

NVDA

Nvidia

$260.13

1.15 (0.44%)

, AMAT

Applied Materials

$47.71

0.22 (0.46%)

12:51
08/16/18
08/16
12:51
08/16/18
12:51
Earnings
Notable companies reporting after market close »

Notable companies…

NVDA

Nvidia

$260.13

1.15 (0.44%)

AMAT

Applied Materials

$47.71

0.22 (0.46%)

JWN

Nordstrom

$51.81

-0.05 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

  • 16

    Aug

ADM

Archer Daniels

$50.05

0.62 (1.25%)

12:45
08/16/18
08/16
12:45
08/16/18
12:45
Recommendations
Archer Daniels analyst commentary  »

Archer Daniels price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

GOOG

Alphabet

$1,225.60

11.95 (0.98%)

, GOOGL

Alphabet Class A

$1,241.50

9.2 (0.75%)

12:38
08/16/18
08/16
12:38
08/16/18
12:38
Periodicals
Google preparing to launch display-equipped speaker for holiday season, NAR says »

Google (GOOGL) is…

GOOG

Alphabet

$1,225.60

11.95 (0.98%)

GOOGL

Alphabet Class A

$1,241.50

9.2 (0.75%)

AMZN

Amazon.com

$1,901.56

20.16 (1.07%)

BABA

Alibaba

$175.08

5.28 (3.11%)

AAPL

Apple

$213.46

3.18 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 22

    Aug

  • 23

    Aug

  • 10

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

SPY

SPDR S&P 500 ETF Trust

$285.01

3.21 (1.14%)

, SPX

S&P 500

$0.00

(0.00%)

12:33
08/16/18
08/16
12:33
08/16/18
12:33
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Mnuchin says U.S.…

SPY

SPDR S&P 500 ETF Trust

$285.01

3.21 (1.14%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$345.54

13.81 (4.16%)

12:32
08/16/18
08/16
12:32
08/16/18
12:32
Hot Stocks
Boeing to acquire Millennium Space Systems, terms not disclosed »

Boeing announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$23.83

0.17 (0.72%)

12:30
08/16/18
08/16
12:30
08/16/18
12:30
Options
One day option play opened in iShares MSCI Hong Kong Fund »

One day option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
08/16/18
08/16
12:17
08/16/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
08/16/18
08/16
12:16
08/16/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
08/16/18
08/16
12:15
08/16/18
12:15
General news
Atlanta Fed's Q3 GPNow estimate was held at 4.3% »

Atlanta Fed's Q3…

CMG

Chipotle

$525.43

-0.44 (-0.08%)

12:14
08/16/18
08/16
12:14
08/16/18
12:14
Periodicals
Chipotle finds cause of foodborne illness at Ohio location, CNBC says »

Chipotle said that tests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

TIF

Tiffany

$127.95

2.23 (1.77%)

, BABA

Alibaba

$175.17

5.37 (3.16%)

12:13
08/16/18
08/16
12:13
08/16/18
12:13
Periodicals
Tiffany to sell on Alibaba's 'Luxury Pavilion' platform on Tmall, Axios reports »

Tiffany & Co (TIF)…

TIF

Tiffany

$127.95

2.23 (1.77%)

BABA

Alibaba

$175.17

5.37 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 28

    Aug

  • 10

    Sep

  • 12

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.